Researcher.Life Logo

Journal of Medical Economics : Impact Factor & More

eISSN: 1941-837XpISSN: 1369-6998

Aims and Scope of Journal of Medical Economics

The Journal of Medical Economics is a monthly peer-reviewed academic journal that covers econometric assessments of novel therapeutic and medical device interventions. It is published by Routledge and was established in 1998. The editor-in-chief is K. Lee. Less

Key Metrics

CiteScore
3.7
H-Index
52
Impact Factor
< 5
SJR
Q2Health Policy
SNIP
0.86
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Journal of Medical Economics

Journal of Medical Economics Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1991
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Journal of Medical Economics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Journal of Medical Economics

Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors
  • 31 Dec 2026
  • Journal of Medical Economics
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making
  • 31 Dec 2026
  • Journal of Medical Economics
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population
  • 31 Dec 2026
  • Journal of Medical Economics
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation
  • 31 Dec 2026
  • Journal of Medical Economics
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States
  • 31 Dec 2026
  • Journal of Medical Economics
The economic burden of moderate-to-severe rheumatoid arthritis in Spain: the CIARA study
  • 31 Dec 2026
  • Journal of Medical Economics
Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors
  • 31 Dec 2026
  • Journal of Medical Economics
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making
  • 31 Dec 2026
  • Journal of Medical Economics
Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population
  • 31 Dec 2026
  • Journal of Medical Economics
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation
  • 31 Dec 2026
  • Journal of Medical Economics
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States
  • 31 Dec 2026
  • Journal of Medical Economics
The economic burden of moderate-to-severe rheumatoid arthritis in Spain: the CIARA study
  • 31 Dec 2026
  • Journal of Medical Economics

FAQs on Journal of Medical Economics